EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

An antibiotic-free platform for eliminating persistent Helicobacter pylori infection without disrupting gut microbiota

Yongkang Lai, Tinglin Zhang, Xiaojing Yin, Chunping Zhu, Yiqi Du, Zhaoshen Li, Jie Gao

Acta Pharmaceutica Sinica B · 2024-07 · 14 (7) · 3184-3204

DOI: 10.1016/j.apsb.2024.03.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2024-07. Verfasst von Yongkang Lai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200433, China. Die Arbeit wurde bisher 96-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Helicobacter pylori (H. pylori) infection remains the leading cause of gastric adenocarcinoma, and its eradication primarily relies on the prolonged and intensive use of two antibiotics. However, antibiotic resistance has become a compelling health issue, leading to H. pylori eradication treatment failure worldwide. Additionally, the powerlessness of antibiotics against biofilms, as well as intracellular H. pylori and the long-term damage of antibiotics to the intestinal microbiota, have also created an urgent demand for antibiotic-free approaches. Herein, we describe an antibiotic-free, multifunctional copper-organic framework (HKUST-1) platform encased in a lipid layer comprising phosphatidic acid (PA), rhamnolipid (RHL), and cholesterol (CHOL), enveloped in chitosan (CS), and loaded in an ascorbyl palmitate (AP) hydrogel: AP@CS@Lip@HKUST-1. This platform targets inflammatory sites where H. pylori aggregates through electrostatic attraction. Then, hydrolysis by matrix metalloproteinases (MMPs) releases CS-encased nanoparticles, disrupting bacterial urease activity and membrane integrity. Additionally, RHL disperses biofilms, while PA promotes lysosomal acidification and activates host autophagy, enabling clearance of intracellular H. pylori. Furthermore, AP@CS@Lip@HKUST-1 alleviates inflammation and enhances mucosal repair through delayed Cu2+ release while preserving the intestinal microbiota. Collectively, this platform presents an advanced therapeutic strategy for eradicating persistent H. pylori infection without inducing drug resistance.

Schlagwörter

Stichwörter der Autor:innen

Anti-inflammationAntibiotic-freeAutophagyBiofilmsDrug resistanceGastric mucosal repairHelicobacter pylori infectionIntestinal microbiota

Autor:innen und Institutionen

  • Department of Gastroenterology, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200433, China.
  • Department of Gastroenterology, Ganzhou People's Hospital Affiliated to Nanchang University, Ganzhou 341000, China.
  • Changhai Clinical Research Unit, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200433, China.
  • National Key Laboratory of Immunity and Inflammation, Naval Medical University, Shanghai 200433, China.
  • Shanghai Key Laboratory of Nautical Medicine and Translation of Drugs and Medical Devices, Shanghai 200433, China.

Zitieren

APA

Lai, Y., Zhang, T., Yin, X., Zhu, C., Du, Y., Li, Z., & Gao, J. (2024). An antibiotic-free platform for eliminating persistent Helicobacter pylori infection without disrupting gut microbiota. Acta Pharmaceutica Sinica B, 14(7), 3184-3204. https://doi.org/10.1016/j.apsb.2024.03.014

Vancouver

Lai Y, Zhang T, Yin X, Zhu C, Du Y, Li Z, et al. An antibiotic-free platform for eliminating persistent Helicobacter pylori infection without disrupting gut microbiota. Acta Pharmaceutica Sinica B. 2024;14(7):3184-3204. doi:10.1016/j.apsb.2024.03.014

BibTeX
@article{Lai2024,
  author = {Lai, Yongkang and Zhang, Tinglin and Yin, Xiaojing and Zhu, Chunping and Du, Yiqi and Li, Zhaoshen and Gao, Jie},
  title = {An antibiotic-free platform for eliminating persistent Helicobacter pylori infection without disrupting gut microbiota},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2024},
  volume = {14},
  number = {7},
  pages = {3184--3204},
  doi = {10.1016/j.apsb.2024.03.014}
}
Kostenlos starten →